HUDDINGE, Sweden, July 28, 2005 (PRIMEZONE) -- LightUp Technologies AB and DakoCytomation A/S today announced the availability of further improved versions of LightUp Technologies' already established ReSSQ(R) CMV and EBV Assays for the monitoring of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in clinical specimens. The new versions feature a range of improvements giving highly accurate and reproducible sample testing and ease of use for the laboratory. The ReSSQ Assays have been demonstrated to be very robust and sensitive, and are validated for use in conjunction with several real-time PCR instrument platforms.
"These enhanced products are the results of LightUp Technologies' continuous strive to improve and extend its product line, which is targeted towards clinical diagnostic laboratories for efficient, accurate and cost effective DNA detection and quantification of viral pathogens," said Ulrica Sehlstedt, Ph.D., Chief Executive Officer and Head of Commercial Operations at LightUp Technologies.
Geoff Gower, Director of Microbiology at DakoCytomation, commented, "We are confident these improved, CE-marked products should meet customers' expectations and prove an important addition to our portfolio." In 2004 DakoCytomation and LightUp Technologies entered into a distribution agreement for LightUp Technologies' infectious disease diagnostic tests based on nucleic acid detection. The agreement grants DakoCytomation co-exclusive rights to market and sell LightUp's products in Europe.
To meet company representatives and learn more about the ReSSQ Assays and the LightUp(R) Probe diagnostic platform technology, stop by the LightUp Technologies and DakoCytomation booth in the exhibition area at the 30th International Herpesvirus Workshop (IHW) from July 30 to August 5 in Turku, Finland.
About LightUp Technologies AB
LightUp Technologies AB is a molecular diagnostic company developing and commercialising products based on its proprietary diagnostic platform technology. Our first product range, the ReSSQ Assays, enables simple, fast and accurate identification and quantification of disease-generating organisms. The unique LightUp Probe at the heart of the method becomes fluorescent - lights up - upon binding to the chosen target DNA and is designed to work with real-time PCR. LightUp Technologies was founded in 1998 and is located in Huddinge, south of Stockholm, Sweden. For more information, visit our web site at www.lightup.se.
About DakoCytomation A/S
DakoCytomation A/S is one of the world's leading providers of system solutions for cancer diagnostics and cell analysis. Hospital and research laboratories worldwide use DakoCytomation products to make precise diagnoses and determine the most effective treatment of patients suffering from cancer and other serious diseases. DakoCytomation is privately owned and headquartered in Denmark. With more than 1300 employees and a presence in more than 20 countries, DakoCytomation covers most of the global market. Remaining markets are covered by distributors in 50 countries. www.dakocytomation.com.
-0- For more information, contact: Ulrica Sehlstedt, Ph.D. CEO & Head of Commercial Operations LightUp Technologies AB Direct line: +46 8 556 40 661 email: ulrica.sehlstedt@lightup.se Anne Thommesen Communications Manager DakoCytomation A/S Cellular phone: +45 40 63 95 93 email: anne.thommesen@dakocytomation.com http://hugin.info/134553/R/1004199/154434.pdf